Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623727 · ClinicalTrials.gov registry record · Phase 2
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT00623727: Clinical Trial Phase 2 study, sponsored by Bayer.
NCT00623727 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 143 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623727, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A.
Primary Outcome
Bleeds occurring on the same day were counted as one bleeding event. Bleeds occurring within 72 hours into the same location were also counted as one bleeding event.
Interventions
- BIOLOGICAL rFVIII-FS/pegylated liposomes (BAY79-4980)
- BIOLOGICAL rFVIII-FS/WFI (BAY14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Why NCT00623727 stopped before completion
NCT00623727 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which rFVIII-FS/pegylated liposomes (BAY79-4980) is the first listed.
NCT00623727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00623727 about?
NCT00623727 is a clinical study titled "BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A". A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A.
What is the current status of trial NCT00623727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2008-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00623727?
The interventions under investigation include: rFVIII-FS/pegylated liposomes (BAY79-4980) (BIOLOGICAL), rFVIII-FS/WFI (BAY14-2222) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00623727?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00623727's enrollment target sits among peer trials
143 507th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia